Little improvement in survival has been made for patients with sarcomas, despite an array of aggressive treatments. Researchers are trying to identify patients at high risk of recurrence by performing FDG PET/CT to quantify necrotic areas of tissue, a strong indicator of survival, according to research published in the July issue of the American Journal of Roentgenology.

The heterogeneity of breast cancer can make it difficult to capture, especially in cases where telltale receptor expression or tumor characterization are not involved. However, MR and F-18 FDG PET may be able to suss out the more obscure phenotypes of the disease, according to a study published July 17 in Radiology.

A newly developed software called Datinrad has combed through extensive literature and compiled more than two hundred radiopharmaceutical interactions and adverse effects is now accessible through a single PC portal, according to an article published July 15 in the Journal of Nuclear Medicine Technology.

Standard methods of evaluation for Alzheimer’s disease (AD) including cognitive tests and one-time PET imaging do not provide a bird’s eye view of disease development. A technique combining a range of examinations and a series of F-18 FDG PET studies is providing researchers valuable information about AD formation, according to research published July 12 in the Journal of Nuclear Medicine.

Rather than looking at the global deposition of beta-amyloid in the brain, it may be more valuable to analyze its spatial pattern, now thought to have a stronger association with memory decline, according to a study published July 15 in Neurobiology of Aging.

Amyloid imaging has been the single stitch holding Alzheimer’s imaging together even though beta-amyloid plaque is typically interwoven in the brain with tangles of tau proteins, but that may soon change as two new tau radiotracers tighten the knit of novel dementia imaging, according to a study published July 15 in the Journal of Nuclear Medicine.

C-11 flumazenil (FMZ) PET has been found to have superior localizing specificity compared with F-18 FDG PET for patients with refractory focal epilepsy. However, there are logistical limitations inherent in the use of C-11. A promising potential alternative is F-18 FMZ, according to a study published July 15 in the Journal of Nuclear Medicine.

RadNet Inc. (Nasdaq:RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 248 subsidiary-owned and/or operated outpatient imaging centers, announced its participation in a clinical trial to evaluate the biomarker effects of the investigational drug E2609, a BACE inhibitor, which is being developed for the potential disease modifying treatment of Alzheimer's disease (AD).